GEOapplication/xmlftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE324nnn/GSE324656/primaryOK200TranscriptomicsHomo sapiensExpression profiling by high throughput sequencinghttps://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE324656GEOGSEfalseMagnetically Actuated Nanoantennas for Wireless Glioblastoma TherapyGlioblastoma (GBM) remains a formidable clinical challenge, characterized by invasive growth, therapeutic resistance and dismal patient survival. We report the development of HITMAN (Highly-localized-electric-field Induced Tumor-therapy using Magnetically Actuated Nanoantennas), a wireless bioelectric therapy that selectively eradicates GBM cells with cellular precision. Magnetically actuated nanoantennas convert low-frequency (≤200 kHz), deep-brain penetrant magnetic fields into localized electric fields (>2 kV m⁻¹), triggering protein unfolding, membrane disruption, and ER stress. In vitro, HITMAN demonstrated superior efficacy compared to temozolomide (TMZ), significantly decreasing viability in drug-resistant, patient-derived GBM cells by 52.2%, versus 10% with TMZ, while sparing neurons and astrocytes. Mechanistically, HITMAN activated unfolded protein response and autophagy pathways, suppressed cell cycle and adhesion genes, reduced Ki-67 expression, disrupted cytoskeletal architecture, and elevated p53 levels, underscoring a multifaceted antitumor mechanism. In orthotopic mouse models, HITMAN significantly inhibited tumor growth, extended median survival by over 50%, and showed no systemic toxicity. Thus, HITMAN offers a minimally invasive, potent, and clinically translatable therapy for GBM.2026/08/31GSE324656GSM9581729GSM9581744GSM9581733GSM9581722GSM9581743GSM9581732GSM9581721GSM9581735GSM9581724GSM9581734GSM9581723GSM9581737GSM9581726GSM9581736GSM9581725GSM9581728GSM9581739GSM9581738GSM9581727GSM9581740GSM9581731GSM9581742GSM9581741GSM958173018573324656Homo sapiens